ValuEngine upgraded shares of Sientra (NASDAQ:SIEN) from a sell rating to a hold rating in a research report released on Saturday morning.
SIEN has been the topic of a number of other research reports. BidaskClub upgraded shares of Sientra from a sell rating to a hold rating in a report on Friday, December 15th. Zacks Investment Research upgraded shares of Sientra from a sell rating to a hold rating in a research note on Tuesday, January 2nd. Canaccord Genuity reiterated a buy rating and issued a $19.00 target price on shares of Sientra in a research note on Friday, January 5th. William Blair reiterated a buy rating on shares of Sientra in a research note on Thursday, March 1st. Finally, Lake Street Capital downgraded shares of Sientra from a buy rating to a hold rating and dropped their target price for the stock from $15.00 to $11.00 in a research note on Wednesday, February 21st. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. Sientra presently has an average rating of Hold and a consensus price target of $13.20.
Shares of Sientra (NASDAQ SIEN) opened at $10.36 on Friday. The firm has a market cap of $199.58, a PE ratio of -3.10 and a beta of -1.10. Sientra has a fifty-two week low of $7.20 and a fifty-two week high of $16.68.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Tuesday, March 13th. The medical instruments supplier reported ($0.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.21). The business had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $11.90 million. Sientra had a negative return on equity of 107.35% and a negative net margin of 175.22%. Sientra’s revenue for the quarter was up 70.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.43) EPS. analysts forecast that Sientra will post -2.68 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of SIEN. Senzar Asset Management LLC lifted its stake in shares of Sientra by 271.6% in the fourth quarter. Senzar Asset Management LLC now owns 484,607 shares of the medical instruments supplier’s stock worth $6,814,000 after buying an additional 354,200 shares in the last quarter. EAM Investors LLC bought a new position in shares of Sientra in the third quarter worth approximately $3,018,000. Pura Vida Investments LLC bought a new position in shares of Sientra in the third quarter worth approximately $2,892,000. X Square Capital LLC bought a new position in shares of Sientra in the fourth quarter worth approximately $2,232,000. Finally, State Street Corp bought a new position in shares of Sientra in the second quarter worth approximately $1,449,000. Hedge funds and other institutional investors own 77.38% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Sientra (SIEN) Lifted to “Hold” at ValuEngine” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://ledgergazette.com/2018/03/20/sientra-sien-lifted-to-hold-at-valuengine.html.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.